|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM33990030X |
| 003 |
DE-627 |
| 005 |
20231226003926.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109017
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1132.xml
|
| 035 |
|
|
|a (DE-627)NLM33990030X
|
| 035 |
|
|
|a (NLM)35460904
|
| 035 |
|
|
|a (PII)S1521-6616(22)00098-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Eiza, N
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The possible involvement of sema3A and sema4A in the pathogenesis of multiple sclerosis
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.05.2022
|
| 500 |
|
|
|a Date Revised 31.05.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022. Published by Elsevier Inc.
|
| 520 |
|
|
|a BACKGROUND: Immune semaphorins are widely accepted to have functional impact on autoimmune diseases
|
| 520 |
|
|
|a OBJECTIVES: To assess the status of sema3A and sema4A in the pathogenesis of Multiple Sclerosis (MS)
|
| 520 |
|
|
|a RESULTS: Sema3A expression on (T regulatory cells)Tregs was decreased in MS patients, compared to healthy controls (35.85 ± 16.7% vs 88.27 ± 3.8%; p ≤ 0.001). Serum levels of sema3A were decreased in MS patients 2.95 ± 0.43 vs 18.67 ± 5.7 ng/ml in healthy individuals; p ≤ 0.001. Sema4A serum levels were increased in MS patients compared to healthy individuals (12.99 ± 8.6 vs 5.83 ± 3.91 ng/ml; p ≤ 0.001). Sema3A and sema4A serum levels were found to be in negative/positive correlation with MS disease severity (rs = 0.62, rs = -0.49, respectively)
|
| 520 |
|
|
|a CONCLUSION: We show that sema3A is a regulatory molecule in MS, whereas sema4A is a stimulatory one. Targeting sema3A and sema4A could become a potential therapeutic approach in MS
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a Multiple sclerosis
|
| 650 |
|
4 |
|a Semaphorins
|
| 650 |
|
4 |
|a T cells
|
| 650 |
|
7 |
|a SEMA3A protein, human
|2 NLM
|
| 650 |
|
7 |
|a SEMA4A protein, human
|2 NLM
|
| 650 |
|
7 |
|a Semaphorin-3A
|2 NLM
|
| 650 |
|
7 |
|a Semaphorins
|2 NLM
|
| 700 |
1 |
|
|a Garty, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Staun-Ram, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Miller, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vadasz, Z
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 238(2022) vom: 01. Mai, Seite 109017
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:238
|g year:2022
|g day:01
|g month:05
|g pages:109017
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109017
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 238
|j 2022
|b 01
|c 05
|h 109017
|